Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Natera's mission is to transform disease management globally through proprietary technology that detects minute quantities of DNA, combining molecular and bioinformatics techniques [2] - The company launched its first product, Panorama, in 2013, a cell-free fetal DNA test for chromosomal abnormalities, and has since become the market leader with over 50% market share [3] - Natera has expanded its technology applications to organ health with Prospera, which non-invasively identifies organ transplant rejection using donor-derived cell-free DNA, and to oncology with Signatera, which monitors minimal residual disease and recurrence through circulating tumor DNA [3]